Wells Fargo & Company MN Has $69,000 Stock Position in Alumis Inc. (NASDAQ:ALMS)

Wells Fargo & Company MN increased its holdings in shares of Alumis Inc. (NASDAQ:ALMS) by 77.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,779 shares of the company’s stock after acquiring an additional 3,823 shares during the quarter. Wells Fargo & Company MN’s holdings in Alumis were worth $69,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Norges Bank bought a new stake in shares of Alumis during the 4th quarter valued at $1,606,000. Towerview LLC increased its stake in shares of Alumis by 9.2% in the fourth quarter. Towerview LLC now owns 415,000 shares of the company’s stock valued at $3,262,000 after buying an additional 35,000 shares during the period. Barclays PLC bought a new stake in shares of Alumis during the 3rd quarter valued at about $197,000. JPMorgan Chase & Co. bought a new stake in shares of Alumis during the 3rd quarter valued at about $191,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Alumis in the 4th quarter valued at $79,000.

Insider Transactions at Alumis

In other Alumis news, CEO Martin Babler acquired 15,650 shares of the business’s stock in a transaction on Tuesday, April 1st. The shares were bought at an average price of $6.44 per share, with a total value of $100,786.00. Following the transaction, the chief executive officer now directly owns 106,454 shares of the company’s stock, valued at $685,563.76. The trade was a 17.23% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Alan Colowick acquired 16,104 shares of the business’s stock in a transaction on Tuesday, April 1st. The stock was acquired at an average cost of $6.97 per share, for a total transaction of $112,244.88. Following the transaction, the director now directly owns 16,104 shares in the company, valued at $112,244.88. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 397,044 shares of company stock valued at $1,891,895 in the last ninety days.

Alumis Price Performance

NASDAQ ALMS opened at $4.46 on Wednesday. Alumis Inc. has a 12 month low of $3.18 and a 12 month high of $13.53. The stock’s 50 day moving average is $5.43 and its 200 day moving average is $7.08.

Wall Street Analysts Forecast Growth

ALMS has been the topic of a number of analyst reports. Oppenheimer began coverage on shares of Alumis in a report on Thursday, January 30th. They set an “outperform” rating and a $32.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of Alumis in a research note on Wednesday, April 30th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a research note on Thursday, March 20th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $25.86.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.